Hudson Bay Capital Management
PTGX icon

Hudson Bay Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Hudson Bay Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,760
Closed -$396K – 1620
2026
Q1 		$396K Sell
3,760
-105,855
-97% -$9.37M ﹤0.01% 1002
2025
Q4 		$9.57M Buy
+109,615
New +$8.97M 0.03% 355

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Hudson Bay Capital Management's PTGX Position: Q2 2026 in Review

Hudson Bay Capital Management sold out of Protagonist Therapeutics (PTGX) in Q2 2026, closing a stake of 3,760 shares — an estimated $396K sold.

Hudson Bay Capital Management first reported a position in PTGX in Q4 2025 and held it in 2 quarters. The position peaked at $9.57M in Q4 2025. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Hudson Bay Capital Management reported no remaining Protagonist Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 3,760 Protagonist Therapeutics shares in Q2 2026, an estimated $396K.
  • Hudson Bay Capital Management first reported a position in Protagonist Therapeutics in Q4 2025 and held it in 2 quarters.
  • Hudson Bay Capital Management's Protagonist Therapeutics position peaked at $9.57M in Q4 2025.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.